Volume : 13, Issue : 03, March – 2026

Title:

ECONOMIC BURDEN OF POLYPHARMACY ON GERIATRIC PATIENTS

Authors :

Syeda Hajra Fatima*, Maahin Rashed, Ayesha Fatima, Muazzam A Barbhuiya, and Mohammad Shamim Qureshi

Abstract :

Polypharmacy is increasingly prevalent among older adults due to population aging and rising multimorbidity, affecting nearly 39% of geriatric individuals and over 59% of frail elderly populations. This review of studies published between 2015 and 2025, identified through major databases including PubMed, MEDLINE, Scopus, and Cochrane Library, evaluates the multidimensional economic burden of polypharmacy among adults aged 65 years and older. Evidence consistently indicates that polypharmacy is associated with nearly a twofold increase in total healthcare expenditure and a substantial rise in pharmacy-related costs. In the United States, older adults exposed to polypharmacy incur significantly higher annual healthcare expenses compared with those without it, and mismanaged polypharmacy contributes billions of dollars in avoidable healthcare spending each year. The economic impact extends beyond direct medication costs to include hospitalizations resulting from adverse drug reactions, emergency department visits, increased outpatient consultations, prolonged hospital stays, caregiver burden, and diminished quality of life. Collectively, these findings underscore the urgent need for evidence-based interventions, such as medication therapy management, structured deprescribing protocols, regular medication review, and interprofessional collaboration, to optimize pharmacotherapy, reduce unnecessary expenditures, and improve clinical outcomes in the geriatric population.
Keywords: Polypharmacy, Geriatric, Economic Burden, Deprescribing, Adverse Drug Reactions, Healthcare Expenditure, Multimorbidity.

Cite This Article:

Please cite this article in press Mohammad Shamim Qureshi et al., Economic Burden Of Polypharmacy On Geriatric Patients ., Indo Am. J. P. Sci, 2026; 13(03)..

REFERENCES:

[1] Wang Z, Liu T, Su Q, et al. Prevalence of polypharmacy in elderly population worldwide: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2024;33(8):e5880. doi:10.1002/pds.5880.
[2] Kim S, Lee H, Park J, et al. Global and regional prevalence of polypharmacy and related factors, 1997–2022: an umbrella review. Arch Gerontol Geriatr. 2024;124:105465. doi:10.1016/j.archger.2024.105465.
[3] Kwak MJ, Chang M, Chiadika S, et al. Healthcare expenditure associated with polypharmacy in older adults with cardiovascular diseases. Am J Cardiol. 2022;169:156–158. doi:10.1016/j.amjcard.2022.01.012.
[4] Polypharmacy and healthcare expenditures among older adults in the United States: a propensity score-matched study. BMC Geriatr. 2025;25:545. doi:10.1186/s12877-025-06545-w.
[5] Lakra K, Pandey M, Meher S, et al. Economic burden of multimorbidity and polypharmacy among geriatric patients: a single-center experience from Odisha, India. Cureus. 2024;16(11):e74752. doi:10.7759/cureus.74752.
[6] Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–834. doi:10.1001/jamainternmed.2015.0324.
[7] Healthcare burden and clinical outcomes of polypharmacy in older adults: a population-based cohort study in South Korea. Arch Public Health. 2025;83:1703. doi:10.1186/s13690-025-01703-3.
[8] Sehgal V, Bajwa SJS, Sehgal R, et al. Polypharmacy and potentially inappropriate medication use as the precipitating factor in readmissions to the hospital. J Fam Med Prim Care. 2013;2(2):194–199.
[9] Associations between chronic disease, polypharmacy, and medication-related problems among Medicare beneficiaries. J Manag Care Spec Pharm. 2023;29(8):921–929. doi:10.18553/jmcp.2023.29.8.921.
[10] Economic evaluations of interventions to optimize medication use in older people with polypharmacy and multimorbidity. Clin Interv Aging. 2021;16:767–781. doi:10.2147/CIA.S304471.
[11] Economic impact of pharmaceutical services on polymedicated patients: a systematic review. Res Social Adm Pharm. 2022;18(10):3766–3775. doi:10.1016/j.sapharm.2022.03.002.
[12] Tackling polypharmacy in geriatric patients: is increasing physicians’ awareness adequate? Saudi Pharm J. 2025;33:100669. doi:10.1016/j.jsps.2025.100669.
[13] Jandu JS, Mohanaselvan A, Dahal R, Bista S. Strategies to reduce polypharmacy in older adults. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Updated August 11, 2024.
[14] Polypharmacy and deprescribing among geriatric patients. Clin Gerontol. 2025;48(3):411–425. doi:10.1016/j.jag.2025.100411.
[15] Polypharmacy and deprescribing in older people. Pharm J. 2025;315(7983). doi:10.1211/PJ.2025.1.325672.
[16] Deprescribing to reduce medication harms in older adults. Making Healthcare Safer IV. AHRQ Publication No. 24-0067. Rockville, MD: Agency for Healthcare Research and Quality; 2024.
[17] World Health Organization. Medication safety in polypharmacy: technical report. Geneva: WHO; 2019. WHO/UHC/SDS/2019.11.
[18] Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi:10.1186/s12877-017-0621-2.
[19] Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74. doi:10.1186/s12916-015-0322-7.
[20] Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review. Lancet Healthy Longev. 2024;5(4):e287–e299. doi:10.1016/S2666-7568(24)00007-2.
[21] Deprescribing and medication optimization in hospitalized older people with multimorbidity and polypharmacy: what larger scale multi-centre clinical trials tell us. Expert Opin Drug Saf. 2025. doi:10.1080/2994399X.2025.2589539.
[22] A pathway to healthier aging or an illusion? A narrative review on deprescribing protocols for the elderly. Innov Aging. 2025;9(7):igaf024. doi:10.1093/geroni/igaf024.
[23] Attitudes and barriers towards deprescribing in older patients experiencing polypharmacy: a narrative review. npj Aging. 2024;10:7. doi:10.1038/s41514-023-00132-2.
[24] Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020;11:2042098620933741. doi:10.1177/2042098620933741.
[25] Polypharmacy management in older patients. Mayo Clin Proc. 2021;96(1):242–256. doi:10.1016/j.mayocp.2020.06.012.
[26] National Institute on Aging. The dangers of polypharmacy and the case for deprescribing in older adults. Bethesda, MD: National Institutes of Health; 2024.
[27] García ALM, Villarreal RE, Galicia RL, et al. Economic cost of polypharmacy in the elderly in primary health care. Rev Med Inst Mex Seguro Soc. 2013;51(2):192–199.
[28] Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J. 2007;9(6):430–434.